Glyco-engineering for biopharmaceutical production in moss bioreactors

09.07.2014

Decker EL, Parsons J, Reski R.

Front Plant Sci. 2014;5:346.

Front Plant Sci.        online article

Physcomitrella patens (moss) can be employed for the recombinant production of high-value therapeutic proteins. As the majority of these are glycoproteins, differences in protein glycosylation between humans and plants have to be considered and plant-specific glycosylation has to be eliminated to avoid adverse effects on quality and safety of the products. Here, we discuss the glyco-engineering approaches to avoid non-human N- and O-glycosylation on target proteins produced in moss bioreactors.